{"title":"pembrolizumab诱导的脐带血移植后肺腺癌患者严重肺炎1例。","authors":"Shunta Yamamoto, Hiroki Kabata, Yuri Fukasawa, Kohei Fukuzawa, Masahito Mizobe, Risako Suzuki, Akira Miyakawa, Keiko Ohgino, Hideki Terai, Jun Kato, Hiroyuki Yasuda, Koichi Fukunaga","doi":"10.1002/rcr2.70307","DOIUrl":null,"url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) are essential treatments for lung cancer, but their safety following allogeneic haematopoietic stem cell transplantation (allo-HSCT) remains unclear. We report a case of a 66-year-old man who underwent umbilical cord blood transplantation for acute lymphoblastic leukaemia and later developed lung adenocarcinoma. Pembrolizumab monotherapy was initiated, but the patient developed severe steroid-refractory immune-related pneumonitis, leading to mortality 56 days after treatment initiation. Given the scarcity of reports on ICI use in lung cancer patients with prior HSCT, this case highlights critical safety considerations.</p>","PeriodicalId":45846,"journal":{"name":"Respirology Case Reports","volume":"13 8","pages":"e70307"},"PeriodicalIF":0.8000,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12322316/pdf/","citationCount":"0","resultStr":"{\"title\":\"Pembrolizumab-Induced Severe Pneumonitis in a Patient With Lung Adenocarcinoma After Umbilical Cord Blood Transplantation: A Case Report.\",\"authors\":\"Shunta Yamamoto, Hiroki Kabata, Yuri Fukasawa, Kohei Fukuzawa, Masahito Mizobe, Risako Suzuki, Akira Miyakawa, Keiko Ohgino, Hideki Terai, Jun Kato, Hiroyuki Yasuda, Koichi Fukunaga\",\"doi\":\"10.1002/rcr2.70307\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Immune checkpoint inhibitors (ICIs) are essential treatments for lung cancer, but their safety following allogeneic haematopoietic stem cell transplantation (allo-HSCT) remains unclear. We report a case of a 66-year-old man who underwent umbilical cord blood transplantation for acute lymphoblastic leukaemia and later developed lung adenocarcinoma. Pembrolizumab monotherapy was initiated, but the patient developed severe steroid-refractory immune-related pneumonitis, leading to mortality 56 days after treatment initiation. Given the scarcity of reports on ICI use in lung cancer patients with prior HSCT, this case highlights critical safety considerations.</p>\",\"PeriodicalId\":45846,\"journal\":{\"name\":\"Respirology Case Reports\",\"volume\":\"13 8\",\"pages\":\"e70307\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2025-08-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12322316/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Respirology Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/rcr2.70307\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respirology Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/rcr2.70307","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
Pembrolizumab-Induced Severe Pneumonitis in a Patient With Lung Adenocarcinoma After Umbilical Cord Blood Transplantation: A Case Report.
Immune checkpoint inhibitors (ICIs) are essential treatments for lung cancer, but their safety following allogeneic haematopoietic stem cell transplantation (allo-HSCT) remains unclear. We report a case of a 66-year-old man who underwent umbilical cord blood transplantation for acute lymphoblastic leukaemia and later developed lung adenocarcinoma. Pembrolizumab monotherapy was initiated, but the patient developed severe steroid-refractory immune-related pneumonitis, leading to mortality 56 days after treatment initiation. Given the scarcity of reports on ICI use in lung cancer patients with prior HSCT, this case highlights critical safety considerations.
期刊介绍：
Respirology Case Reports is an open-access online journal dedicated to the publication of original clinical case reports, case series, clinical images and clinical videos in all fields of respiratory medicine. The Journal encourages the international exchange between clinicians and researchers of experiences in diagnosing and treating uncommon diseases or diseases with unusual presentations. All manuscripts are peer-reviewed through a streamlined process that aims at providing a rapid turnaround time from submission to publication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
